Minerva Neurosciences | NERV - Market Capitalization


Minerva Neurosciences reported $16.1M in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
Adma Biologics USD 2.7B 757M Nov/2026
ALKERMES USD 7.39B 595M Nov/2026
Alterity Therapeutics Limited AUD 39M 17M Sep/2026
AstraZeneca USD 213.88B 23.43B Nov/2026
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Cipla INR 1.09T 96.42B Sep/2026
Clal Biotechnology ILS 52.36M 2.09M Mar/2025
Compugen USD 564.53M 41.47M Nov/2026
CSL USD 55.89B 20.42B Dec/2025
Eli Lilly USD 1.09T 40.33B Sep/2026
GlaxoSmithKline GBP 74.11B 6.03B Sep/2026
Halozyme Therapeutics USD 15.62B 3.09B Nov/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
J&J USD 653.61B 42.25B Sep/2026
Merck USD 375.59B 17.09B Nov/2026
Neurocrine Biosciences USD 14.46B 45M Nov/2026
Novartis USD 292.09B 51.5B Sep/2026
Novavax USD 1.09B 316M Dec/2025
Pfizer USD 169.88B 6.47B Nov/2026
Roche Holding CHF 270B 3.66B Jun/2026
Sanofi EUR 100.56B 13.53B Nov/2026
Takeda JPY 9.26T 1.06T Sep/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024